Preferred Label : EGFR Mutant-selective Inhibitor BBT-207;
NCIt synonyms : Mutant-selective EGFR Inhibitor BBT-207; Epidermal Growth Factor Receptor Mutant-selective Inhibitor BBT-207;
NCIt definition : A fourth-generation, orally bioavailable, mutant-selective, epidermal growth factor
receptor (EGFR) inhibitor, with potential antineoplastic activity. Upon oral administration,
EGFR mutant-selective inhibitor BBT-207 targets, reversibly binds to, and inhibits
the activity of various sensitizing and treatment-emergent EGFR mutations, including
ones involving C797S and T790M mutations, and activating mutations, involving exon
19 deletion and L858R mutations. This prevents EGFR-mediated signaling, induces cell
death and inhibits growth in susceptible tumor cells harboring these mutations. EGFR,
a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor
cell proliferation and tumor vascularization. BBT-207 may overcome resistance to third-generation
EGFR inhibitors and may be active against drug-naive mutants.;
Molecule name : BBT-207; BBT 207;
Origin ID : C218465;
concept_is_in_subset
- has_target
